Time to chemotherapy (exploratory analysis)
These results were observational in nature; as such, there was no prespecified statistical procedure controlling for type 1 error. Results should be interpreted with caution due to the limitations of exploratory analyses.
Adapted from Slamon DJ, et al. 2021.1
Time to chemotherapy was an exploratory endpoint and was defined as the time from randomisation to the initiation of chemotherapy after discontinuing study treatment.1
In an exploratory analysis, KISQALI + fulvestrant was observed to delay the need for chemotherapy by 19.3 months vs placebo + fulvestrant1
CI, confidence interval; CT, chemotherapy; HR, hazard ratio.
Reference
1. Slamon DJ, et al. Ann Oncol 2021;32(8):1015–1024.
